PDCD1 and hepatocellular carcinoma: Within the independent HCC cohort treated with anti-PD-1 monotherapy21 (Extended Data Fig. 6e,f), both responders and non-responders exhibited no changes either in the proportion of subcluster (Extended Data Fig. 6g) or in the expression levels of gene set module scores related to regorafenib responsiveness or CSF1R knockout after anti-PD-1 therapy (Extended Data Fig. 6h,i).